Skip to main content
Erschienen in: European Journal of Pediatrics 2/2012

01.02.2012 | Case Report

A patient with Dent disease and features of Bartter syndrome caused by a novel mutation of CLCN5

verfasst von: Takayuki Okamoto, Toshihiro Tajima, Tomoya Hirayama, Satoshi Sasaki

Erschienen in: European Journal of Pediatrics | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Dent disease is an X-linked tubulopathy mainly caused by inactivating mutations of CLCN5. Features of Bartter syndrome such as hypokalemic metabolic alkalosis are rarely observed in patients with Dent disease. We report a Japanese male patient with Dent disease who also manifested features of Bartter syndrome. At the age of 3 years, he was diagnosed with Dent disease based on low molecular weight proteinuria and hypercalciuria. One year later, he was found to have features of Bartter syndrome, i.e., hypokalemia and metabolic alkalosis, and high levels of plasma renin activity and aldosterone with a normal blood pressure. Despite medical interventions, he developed chronic kidney disease stage 3 at the age of 21 years. To investigate the molecular basis of his disease, CLCN5, KCNJ1, SLC12A1, and CLCkb were analyzed and a novel mutation (Y567X) in CLCN5 was identified. Conclusion: Hypokalemic metabolic alkalosis is a rare manifestation in Dent disease. It is speculated that Dent patients with features of Bartter syndrome are susceptible to progression to renal failure. To study this hypothesis, additional observations and long-term follow-up of such patients are necessary.
Literatur
1.
Zurück zum Zitat Akil I, Ozen S, Kandiloglu AR, Ersoy B (2010) A patient with Bartter syndrome accompanying severe growth hormone deficiency and focal segmental glomerulosclerosis. Clin Exp Nephrol 14:278–282PubMedCrossRef Akil I, Ozen S, Kandiloglu AR, Ersoy B (2010) A patient with Bartter syndrome accompanying severe growth hormone deficiency and focal segmental glomerulosclerosis. Clin Exp Nephrol 14:278–282PubMedCrossRef
2.
Zurück zum Zitat Besbas N, Ozaltin F, Jeck N, Seyberth H, Ludwig M (2005) CLCN5 mutation (R347X) associated with hypokalemic metabolic alkalosis in a Turkish child: an unusual presentation of Dent’s disease. Nephrol Dial Transplant 20:1476–1479PubMedCrossRef Besbas N, Ozaltin F, Jeck N, Seyberth H, Ludwig M (2005) CLCN5 mutation (R347X) associated with hypokalemic metabolic alkalosis in a Turkish child: an unusual presentation of Dent’s disease. Nephrol Dial Transplant 20:1476–1479PubMedCrossRef
3.
Zurück zum Zitat Bogdanovic R, Draaken M, Toromanovic A, Dordevic M, Stajic N, Ludwig M (2010) A novel CLCN5 mutation in a boy with Bartter-like syndrome and partial growth hormone deficiency. Pediatr Nephrol 25:2363–2368PubMedCrossRef Bogdanovic R, Draaken M, Toromanovic A, Dordevic M, Stajic N, Ludwig M (2010) A novel CLCN5 mutation in a boy with Bartter-like syndrome and partial growth hormone deficiency. Pediatr Nephrol 25:2363–2368PubMedCrossRef
4.
Zurück zum Zitat Christensen EI, Devuyst O, Dom G, Nielsen R, Van der Smissen P, Verroust P, Leruth M, Guggino WB, Courtoy PJ (2003) Loss of chloride channel CLC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci USA 100:8472–8477PubMedCrossRef Christensen EI, Devuyst O, Dom G, Nielsen R, Van der Smissen P, Verroust P, Leruth M, Guggino WB, Courtoy PJ (2003) Loss of chloride channel CLC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci USA 100:8472–8477PubMedCrossRef
5.
Zurück zum Zitat Claverie-Martin F, Ramos-Trujillo E, Garcia-Nieto V (2011) Dent’s disease: clinical features and molecular basis. Pediatr Nephrol 26:693–704PubMedCrossRef Claverie-Martin F, Ramos-Trujillo E, Garcia-Nieto V (2011) Dent’s disease: clinical features and molecular basis. Pediatr Nephrol 26:693–704PubMedCrossRef
6.
Zurück zum Zitat Copelovitch L, Nash MA, Kaplan BS (2007) Hypothesis: Dent disease is an underrecognized cause of focal glomerulosclerosis. Clin J Am Soc Nephrol 2:914–918PubMedCrossRef Copelovitch L, Nash MA, Kaplan BS (2007) Hypothesis: Dent disease is an underrecognized cause of focal glomerulosclerosis. Clin J Am Soc Nephrol 2:914–918PubMedCrossRef
7.
Zurück zum Zitat Fukushige J, Shimomura K, Ueda K (1994) Influence of upright activity on plasma rennin activity and aldosterone concentration in children. Eur J Pediatr 153:284–286PubMedCrossRef Fukushige J, Shimomura K, Ueda K (1994) Influence of upright activity on plasma rennin activity and aldosterone concentration in children. Eur J Pediatr 153:284–286PubMedCrossRef
8.
Zurück zum Zitat Kaneko K, Hasui M, Hata A, Nozu K (2010) Focal segmental glomerulosclerosis in a boy with Dent-2 disease. Pediatr Nephrol 25:781–782PubMedCrossRef Kaneko K, Hasui M, Hata A, Nozu K (2010) Focal segmental glomerulosclerosis in a boy with Dent-2 disease. Pediatr Nephrol 25:781–782PubMedCrossRef
9.
Zurück zum Zitat Schachter AD, Arbus GS, Alexander RJ, Balfe JW (1998) Non-steroidal anti-inflammatory drug-associated nephrotoxicity in Bartter syndrome. Pediatr Nephrol 12:775–777PubMedCrossRef Schachter AD, Arbus GS, Alexander RJ, Balfe JW (1998) Non-steroidal anti-inflammatory drug-associated nephrotoxicity in Bartter syndrome. Pediatr Nephrol 12:775–777PubMedCrossRef
10.
Zurück zum Zitat Sheffer-Babila S, Chandra M, Speiser PW (2008) Growth hormone improves growth rate and preserves renal function in Dent disease. J Pediatr Endocrinol Metab 21:279–286PubMedCrossRef Sheffer-Babila S, Chandra M, Speiser PW (2008) Growth hormone improves growth rate and preserves renal function in Dent disease. J Pediatr Endocrinol Metab 21:279–286PubMedCrossRef
11.
Zurück zum Zitat Su IH, Frank R, Gauthier BG, Valderrama E, Simon DB, Lifton RP, Trachtman H (2000) Bartter syndrome and focal segmental glomerulosclerosis: a possible link between two diseases. Pediatr Nephrol 14:970–972PubMedCrossRef Su IH, Frank R, Gauthier BG, Valderrama E, Simon DB, Lifton RP, Trachtman H (2000) Bartter syndrome and focal segmental glomerulosclerosis: a possible link between two diseases. Pediatr Nephrol 14:970–972PubMedCrossRef
12.
Zurück zum Zitat Tosetto E, Ghiggeri GM, Emma F, Barbano G, Carrea A, Vezzoli G, Torregrossa R, Cara M, Ripanti G, Ammenti A, Peruzzi L, Murer L, Ratsch IM, Citron L, Gambaro G, D’angelo A, Anglani F (2006) Phenotypic and genetic heterogeneity in Dent’s disease—the results of an Italian collaborative study. Nephrol Dial Transplant 21:2452–2463PubMedCrossRef Tosetto E, Ghiggeri GM, Emma F, Barbano G, Carrea A, Vezzoli G, Torregrossa R, Cara M, Ripanti G, Ammenti A, Peruzzi L, Murer L, Ratsch IM, Citron L, Gambaro G, D’angelo A, Anglani F (2006) Phenotypic and genetic heterogeneity in Dent’s disease—the results of an Italian collaborative study. Nephrol Dial Transplant 21:2452–2463PubMedCrossRef
13.
Zurück zum Zitat Yamazaki H, Nozu K, Narita I, Nagata M, Nozu Y, Fu XJ, Matsuo M, Iijima K, Gejyo F (2009) Atypical phenotype of type I Bartter syndrome accompanied by focal segmental glomerulosclerosis. Pediatr Nephrol 24:415–418PubMedCrossRef Yamazaki H, Nozu K, Narita I, Nagata M, Nozu Y, Fu XJ, Matsuo M, Iijima K, Gejyo F (2009) Atypical phenotype of type I Bartter syndrome accompanied by focal segmental glomerulosclerosis. Pediatr Nephrol 24:415–418PubMedCrossRef
Metadaten
Titel
A patient with Dent disease and features of Bartter syndrome caused by a novel mutation of CLCN5
verfasst von
Takayuki Okamoto
Toshihiro Tajima
Tomoya Hirayama
Satoshi Sasaki
Publikationsdatum
01.02.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Pediatrics / Ausgabe 2/2012
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-011-1578-3

Weitere Artikel der Ausgabe 2/2012

European Journal of Pediatrics 2/2012 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.